Biological Evaluation of Anticoagulant Activity in Animals: Principles, Standards, and Testing Metho

Biological evaluation of anticoagulant activity in animals is a core element of hemocompatibility testing for blood-contacting medical devices, heparin-coated surfaces, and anticoagulant substances. Guided by ISO 10993-4 and the corresponding GB/T 16886 series, these assessments combine in vitro coagulation assays with validated animal thrombosis models to quantify how a material or compound modifies the coagulation system. This article explains the scientific rationale, sample types, test items, methodologies, and regulatory applications of animal-based anticoagulant activity evaluation.

Technical Overview

Anticoagulant activity refers to the capacity of a test article—whether a device surface, a functional coating, a material extract, or a pharmacologically active compound—to inhibit, delay, or otherwise modify the blood coagulation cascade. Biological evaluation of this activity in animal systems measures changes in clotting function when animal blood, plasma, or a living animal is exposed to the test article under controlled laboratory conditions. The evaluation is a recognized part of the hemocompatibility assessment described in ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood) and its Chinese national adoption, GB/T 16886.4.

The coagulation system comprises the intrinsic pathway (factors VIII, IX, XI, and XII), the extrinsic pathway (tissue factor and factor VII), and the common pathway (factors X and V, prothrombin, and fibrinogen). Anticoagulant effects can act at any point in this network: heparin potentiates antithrombin III to neutralize thrombin and factor Xa, direct thrombin inhibitors block fibrin formation, and some material surfaces or leachables indirectly consume clotting factors. Laboratory assays are mapped to these pathways so that a specific mechanism can be inferred from the pattern of results. The activated partial thromboplastin time (APTT) probes the intrinsic pathway, the prothrombin time (PT) probes the extrinsic pathway, and the thrombin time (TT) reflects the final conversion of fibrinogen to fibrin.

Within the ISO 10993-4 framework, blood–device interactions are divided into five categories: thrombosis, coagulation, platelets, hematology, and the complement system. Anticoagulant activity evaluation belongs primarily to the coagulation category, but it is frequently performed together with thrombosis, platelet, hemolysis, and complement assays as an integrated hemocompatibility panel. Depending on the intended use and the nature of blood contact, testing may follow in vitro, ex vivo, or in vivo designs, and all animal work must comply with ISO 10993-2 (animal welfare requirements), the 3Rs principles, and institutional ethical review. Studies of this type are normally carried out by accredited third-party laboratories with GLP-compliant facilities and validated coagulation analytical systems.

Testing Samples

Blood-Contacting Medical Devices

• Central venous and arterial catheters, guidewires, and introducer sheaths
• Vascular grafts, stents, stent-grafts, and heart valves
• Extracorporeal circulation components such as oxygenators, hemodialyzers, blood filters, and tubing sets
• Blood bags, transfusion and infusion sets, and apheresis consumables

Anticoagulant and Thromboresistant Coatings

• Heparin-coated or heparin-immobilized surfaces
• Hydrophilic, albumin-bound, or phosphorylcholine-based coatings claimed to reduce thrombus formation
• Drug-eluting surfaces carrying antithrombotic agents

Anticoagulant Substances and Material Extracts

• Unfractionated heparin, low-molecular-weight heparin, and heparinoids
• Direct thrombin inhibitors such as hirudin and its engineered derivatives
• Device extracts prepared according to ISO 10993-12 at standard surface-area-to-volume or mass-to-volume ratios

Biomaterials and Research Candidates

• New polymers, hydrogels, and nanomaterials intended for blood contact
• Natural or chemically modified polysaccharides with suspected anticoagulant properties
• Functional wound dressings and anti-thrombogenic products under development

Testing Items

A complete evaluation program typically combines coagulation function assays, quantitative activity assays for known anticoagulants, and supplementary hemocompatibility endpoints:

• Activated partial thromboplastin time (APTT) — intrinsic pathway function
• Prothrombin time (PT) — extrinsic (tissue factor) pathway function
• Thrombin time (TT) and reptilase time — fibrin formation and heparin-like effects
• Plasma fibrinogen concentration (Clauss method)
• Plasma recalcification time and activated clotting time (ACT)
• Thrombin generation assays (lag time, peak thrombin, endogenous thrombin potential)
• Anti-Factor Xa and anti-Factor IIa chromogenic activity assays for heparin quantification
• Plasma-clotting potency assays calibrated against international biological reference standards
• Platelet count, platelet adhesion, and platelet aggregation studies
• Thrombus mass (wet and dry weight), blood flow, and vessel occlusion time in animal models
• Complement activation markers (C3a, C5a, SC5b-9) and plasma hemoglobin as companion hemocompatibility endpoints
• Serial coagulation markers in animal blood samples, including APTT, PT, fibrinogen, D-dimer, and antithrombin III

Testing Methods

Sample Preparation and Blood Collection

Test articles are prepared in accordance with ISO 10993-12, using either direct-contact coupons of the finished device or polar and non-polar extracts at standardized ratios. Blood is collected from healthy rabbits, sheep, rats, or pigs. For clot-based coagulation assays, blood is drawn into trisodium citrate, platelet-poor plasma is prepared by centrifugation, and testing is completed within defined time windows to preserve labile clotting factors. For in vivo studies, animals are acclimatized, fasted where appropriate, and anesthetized under approved protocols.

In Vitro Coagulation Assays

Citrated animal plasma or recalcified whole blood is incubated with the test article or its extract under static conditions, after which APTT, PT, TT, fibrinogen, and recalcification time are measured on mechanical or optical coagulometers. Results are compared with a negative control (vehicle or reference material) and a positive control such as heparin. A statistically significant, dose- or contact-dependent prolongation of clotting times indicates that anticoagulant activity is present or leaching from the sample, and the pattern across assays helps identify the pathway involved.

Chromogenic and Potency Assays

For heparin and heparin-like substances, activity is quantified using chromogenic anti-Factor Xa or anti-Factor IIa amidolytic assays, in which the sample is incubated with antithrombin III and the target protease, and residual enzyme activity is measured with a synthetic substrate. Alternatively, compendial plasma-clotting assays using sheep or rabbit plasma determine potency in International Units (IU) against a calibrated reference standard. These methods distinguish the specific anticoagulant potency of a coating or raw material from nonspecific effects on the cascade.

In Vivo Thrombosis and Anticoagulation Models

• Rabbit or rat jugular and femoral vein thrombosis model — a device segment or material coupon is inserted into the vessel, and thrombus mass plus vessel histopathology are assessed after a defined exposure period of one to four hours
• Arteriovenous shunt model in rats — circulating blood passes over the test material in an exteriorized shunt, and thrombus dry weight serves as the primary quantitative endpoint
• Stasis or ferric chloride-induced venous thrombosis models for screening the antithrombotic efficacy of systemically administered compounds
• Tail transection bleeding time and cuticle bleeding models to characterize systemic anticoagulant effect and hemorrhagic risk
• Ex vivo extracorporeal circuit models in anesthetized animals to evaluate circuit patency, visible clotting, and pressure rise under physiological flow

Study Design, Controls, and Statistics

Typical in vivo designs include a negative control group, a positive anticoagulant control group (for example, heparin-treated animals), and at least three dose or contact groups, with animal numbers justified by statistical power analysis. Endpoints such as thrombus weight, clotting times, and coagulation biomarkers are analyzed by ANOVA with appropriate post hoc tests or non-parametric equivalents. All procedures follow the 3Rs principles—replacement, reduction, and refinement—under ISO 10993-2 and are approved by an institutional animal ethics committee before initiation.

Applications

• Regulatory submissions for blood-contacting medical devices under ISO 10993-4 and GB/T 16886.4 for national device registration and international market access
• Development, optimization, and batch-to-batch consistency verification of heparin-coated devices and extracorporeal circuits
• Preclinical screening and potency confirmation of new anticoagulant compounds, sulfated polysaccharides, and biologics
• Comparative evaluation of surface modification strategies intended to improve thromboresistance
• Quality control and potency assignment of animal-derived heparin raw materials
• Academic and industrial research on coagulation mechanisms, biomaterial safety, and nanomedicine blood compatibility

FAQ

Which animal species are most commonly used?

Rabbits and rats are the most frequently used species for in vivo thrombosis models because their vessels accommodate standard device segments and their coagulation physiology is well characterized. Rabbit and sheep blood or plasma are preferred for in vitro coagulation and heparin potency assays, as their clotting systems respond predictably and reproducibly to heparin.

What is the difference between in vitro and in vivo anticoagulant evaluation?

In vitro tests expose animal blood or plasma to the sample under controlled static conditions and measure clotting time changes, providing a sensitive screen for leachable anticoagulants. In vivo tests examine actual thrombus formation, blood flow, and systemic coagulation changes in living animals under physiological shear and flow, capturing endothelial and protein-adsorption effects that static tests cannot reproduce. Regulatory strategies for higher-risk devices usually require both.

Which standards govern the evaluation?

The primary standards are ISO 10993-4 for blood interaction testing, ISO 10993-12 for sample preparation, and ISO 10993-2 for animal welfare, together with the GB/T 16886 series in China and applicable pharmacopoeial heparin potency monographs. Companion endpoints such as hemolysis may reference ASTM F756, and complement assays follow recognized immunological methods.

How is heparin activity expressed?

Heparin activity is expressed in International Units (IU), determined by anti-Factor Xa or anti-Factor IIa chromogenic assays or by plasma-clotting assays calibrated against an international biological reference standard. For coated devices, results may additionally be reported as retained activity per unit surface area after extraction or contact.

How long does a typical evaluation take?

In vitro coagulation panels generally require two to four weeks including method validation. In vivo thrombosis studies, which include ethical approval, animal acclimatization, surgery, dosing, and histopathology, commonly require six to twelve weeks depending on the model and number of groups.

Can animal use be reduced in this type of testing?

Yes. Consistent with the 3Rs principles, validated in vitro assays using animal or human blood, microfluidic flow chambers, and computational screening are increasingly used for early-tier evaluation. However, in vivo confirmation remains necessary for long-term, high-risk blood-contacting devices and for systemic anticoagulant candidates, because whole-organism effects cannot yet be fully reproduced in vitro.